An interventional study of ketamine bolus and ketamin infusion in Laparoscopic Cholecystectomy, Optic Nerve Sheath Diameter Measurement and Ketamine, sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital · Not applicable, Interventional, and Prevention
This prospective, randomized, controlled study evaluated the effects of different ketamine administration strategies in adult patients undergoing elective laparoscopic cholecystectomy under general anesthesia. Participants were randomized into three groups: bolus ketamine, continuous ketamine infusion, or control without ketamine. The study investigated the effects of these strategies on optic nerve sheath diameter measured by ultrasonography as a surrogate marker of intracranial pressure, intraoperative sevoflurane consumption, and postoperative pain and analgesic requirements.
5,259 studies on the registry are indexed under Pain, Postoperative; 1,163 are open to participants now.
This study's enrollment of 102 is above the median of 75 across 4,490 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received intravenous ketamine 0.25 mg/kg as a bolus after induction of anesthesia. The dose was repeated if the duration of surgery exceeded 60 minutes.
Drug: ketamine bolus
Participants received intravenous ketamine at 0.25 mg/kg/hour, initiated after induction of anesthesia and continued until the end of surgery.
Drug: ketamin infusion
Participants did not receive ketamine and received 100 mL normal saline according to the study protocol.
Other: Normal Saline
Ketamine 0.25 mg/kg was administered intravenously as a bolus after the initiation of remifentanil infusion following endotracheal intubation. The same dose was repeated if the duration of surgery exceeded 60 minutes.
Ketamine was administered intravenously at 0.25 mg/kg/hour after the initiation of remifentanil infusion following endotracheal intubation and was continued until the end of surgery.
Participants in the control group did not receive ketamine. A 100 mL normal saline infusion was initiated concurrently with the remifentanil infusion.
Optic Nerve Sheath Diameter
Optic nerve sheath diameter (ONSD) was measured using ocular ultrasonography. Measurements were obtained bilaterally at 3 mm posterior to the globe, and the mean of four consecutive measurements was recorded. ONSD was evaluated to assess changes associated with different ketamine administration strategies during laparoscopic cholecystectomy.
Time frame: Pre-anesthesia; 5 minutes after intubation; 5 minutes after initiation of the study intervention; 5 minutes after pneumoperitoneum; 5 minutes after reverse Trendelenburg positioning; 30 minutes after intubation; and 5 minutes after desufflation.
Optic Nerve Sheath Diameter
Time frame: Pre-anesthesia; 5 minutes after intubation; 5 minutes after initiation of the study intervention; 5 minutes after pneumoperitoneum; 5 minutes after reverse Trendelenburg positioning; 30 minutes after intubation; and 5 minutes after desufflation.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital